This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Oncosec Medical Incorporated. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: David A. Canton: Innovator in Immunomodulatory Protein Expression
Introduction
David A. Canton is a notable inventor based in Poway, California. He has made significant contributions to the field of biotechnology, particularly in the development of plasmid constructs for protein expression. His work focuses on enhancing therapeutic potential through innovative genetic engineering techniques.
Latest Patents
David A. Canton holds a patent for "Plasmid constructs for heterologous protein expression and methods of use." This patent includes plasmid vector constructs that encode multiple immunomodulatory proteins. Each protein can be expressed using appropriate promoters and translation modifiers. The invention also allows for the addition of further immunomodulatory proteins and genetic adjuvants containing shared tumor antigens, enhancing therapeutic potential and enabling tracking of treatment. Additionally, the patent provides methods for expressing these plasmid constructs.
Career Highlights
Canton is associated with Oncosec Medical Incorporated, a company focused on developing innovative cancer therapies. His work at the company has been instrumental in advancing the understanding and application of immunomodulatory proteins in therapeutic settings.
Collaborations
David A. Canton has collaborated with notable colleagues, including Jean Campbell and Robert H. Pierce. Their combined expertise contributes to the innovative research and development efforts at Oncosec Medical Incorporated.
Conclusion
David A. Canton is a pioneering inventor whose work in plasmid constructs and immunomodulatory proteins has the potential to significantly impact cancer treatment. His contributions to biotechnology exemplify the importance of innovation in addressing complex medical challenges.